4166.TWO Orient Pharma Co. Ltd.
- Market cap
- TWD 5.50B
- P/E
- 23.1x
- P/B
- 2.08x
- ROE
- 7.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4166.TWO undervalued?
Graham number4166.TWO trades 46.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orient Pharma Co. Ltd. fundamental analysis
No fundamental analysis for Orient Pharma Co. Ltd. yet.
Orient Pharma Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.
Full company profileOrient Pharma Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Orient Pharma Co. Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 354M | 412M | 463M | 512M | 890M | 1.22B | 1.40B | 1.52B |
| Gross Profit | 13.7M | 75.2M | 143M | 155M | 469M | 652M | 791M | 821M |
| Operating Income | -205M | -160M | -104M | -33.7M | 40.3M | 174M | 267M | 266M |
| EBITDA | -151M | -93.7M | -39.2M | 35.4M | 176M | 313M | 388M | 396M |
| Net Income | -201M | -171M | -103M | -28.8M | 22.3M | 107M | 208M | 192M |
| EPS | -1.29 | -1.01 | -0.55 | -0.15 | 0.10 | 0.48 | 0.86 | 0.79 |
| Balance Sheet | ||||||||
| Total Assets | 1.56B | 1.74B | 1.76B | 1.85B | 2.56B | 2.52B | 2.94B | 3.01B |
| Total Liabilities | 1.60M | 526M | 648M | 758M | 892M | 733M | 375M | 354M |
| Shareholders' Equity | 985M | 1.22B | 1.12B | 1.09B | 1.67B | 1.79B | 2.56B | 2.66B |
| Cash & Short-term Investments | 58.1M | 190M | 152M | 97.2M | 113M | 84.5M | 588M | 575M |
| Total Debt | 359M | 324M | 415M | 508M | 717M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -130M | -148M | -53.6M | 11.4M | -103M | 196M | 360M | 254M |
| Capital Expenditure | 25.4M | 74.4M | 70.0M | 28.9M | 73.5M | 27.4M | 49.5M | 120M |
| Free Cash Flow | -155M | -222M | -124M | -17.5M | -177M | 168M | 310M | 134M |
| Ratios | ||||||||
| ROE | -20.4% | -14.1% | -9.2% | -2.6% | 1.3% | 6.0% | 8.1% | 7.2% |
| ROA | -12.9% | -9.8% | -5.8% | -1.6% | 0.9% | 4.3% | 7.1% | 6.4% |
| Net Profit Margin | -56.9% | -41.6% | -22.2% | -5.6% | 2.5% | 8.8% | 14.9% | 12.7% |
| Debt to Equity | 0.36x | 0.27x | 0.37x | 0.47x | 0.43x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Orient Pharma Co. Ltd. dividends
Orient Pharma Co. Ltd. has not paid dividends in the last 7 fiscal years.
Who owns Orient Pharma Co. Ltd.
- Insiders 76.53%
- Institutions 0.00%
- Public & others 23.47%
- Shares outstanding 243M
- Free float 57.2M
Orient Pharma Co. Ltd. company profile
- Company name
- Orient Pharma Co. Ltd.
- Ticker
- 4166.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Central Science Park, Taipei, Taiwan, 106
- Phone
- 886 2 2325 7621
- Website
- oppharma.com
About Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.
Orient Pharma Co. Ltd. management
3- Mr. Chun-Tong HuangGeneral Manager
- Yi Xin ZhangChief Financial Officer
- Zhi Cheng LuChief Operating Officer